In families with X-linked chronic granulomatous disease (CGD), heterozygous females have two stable populations of polymorphonuclear leukocytes (PMN) in their blood; one normal, the other, deficient in oxygen metabolism. The two types of PMN can be distinguished by the ability or lack of ability to reduce nitroblue tetrazolium dye. The variation in the percent normal PMN among 11 CGD heterozygotes was shown to follow a binomial distribution based on eight independent trials and a chance of success of 50%. This is consistent with the occurrence of Xchromosome inactivation (1yonization) when eight embryonic founder cells for the hematopoietic system are present. Serial determinations of the percent normal PMN in individual heterozygotes showed very limited variability (standard deviations ranged from 2.0% to 5.2%) most of which could be ascribed to experimental error. An estimate of the remaining variation (residual variance) was introduced into a well-known formula to calculate the appropriate number of pluripotent stem cells necessary to support hematopoiesis and a figure exceeding 400 was obtained. Thus, the data indicate that in humans there is a highly polyclonal system of hematopoiesis.
Introduction
Chronic granulomatous disease (CGD)' of childhood is an inherited group of diseases recognized only in humans, in which phagocytic leukocytes have a deranged oxygen metabolism, with a consequent defect in killing ofcatalase-positive microorganisms (1) . One form ofCGD is an X-linked recessive disorder in which males are severely affected and half oftheir female relatives can be expected to be heterozygous carriers for the disease (2) . Such carriers can almost always be shown to have two distinct populations of phagocytic cells in their blood, one with competent oxygen metabolism, the other, without. The proportions ofcells belonging to the two populations are thought to be established by random X-chromosome inactivation early in ontogeny (2) . Assays that detect competent oxygen metabolism in individual cells, such as nitroblue tetrazolium (NBT) reduction, can readily be applied to purified preparations ofphagocytic cells from CGD heterozygotes to study population dynamics of polymorphonuclear leukocytes (PMN).
CGD heterozygotes. 11 females heterozygous for CGD were identified using the NBT reduction assay described below. All subjects were relatives of patients previously documented in the literature (1) and included seven mothers of male patients with X-linked CGD and one maternal grandmother of two brothers with X-linked CGD.
NBT reduction assay. The slide NBT test of Repine et al. (3) was modified as follows: 0.5-1.0 ml of fresh whole blood was placed on a glass slide and incubated at 370C in a humidified chamber until clotting occurred (1.5-3 h). After the clot was gently removed the slide was rinsed in phosphate-buffered saline (PBS) to free it of erythrocytes, then covered with a solution containing 0.1% NBT and 20 ng/ml phorbQl myristate acetate (both obtained from Sigma Chemical Co., St. Louis, MO) in Hanks' balanced salt solution with calcium and magnesium. The slide was incubated for 15 min at 370C, then rinsed in PBS, air-dried, and counterstained with 0.25% safranine. 300-500 cells were identified as PMN by nuclear morphology and scored as either NBT positive or NBT negative. Neutrophils from 10 normal subjects were studied using this method and showed an average of 99.6±0.18% cells that reduced NBT (range 98.5-100%).
Statistical methods.
(a) The mean percent PMN positive for NBT in a heterozygote was assumed to follow a binomial distribution based on eight independent trials and a chance of success of 50%; that is, Results 11 healthy females were studied over periods of time up to 2.5 yr. Each of these subjects had both NBT-positive and NBTnegative PMN in her peripheral blood and each was a close relative of a patient with CGD. In view ofthe latter findings, we assumed that the subjects were CGD heterozygotes. The distribution ofthe mean percentage ofPMN positive for NBT among the subjects is shown in the lower panel of Fig. 1 . The average of the mean percentages is 53.8%, which is not significantly different from 50%, the predicted average if the chance were 50% that the normal X-chromosome is inactivated (Lyon hypothesis [4] ). If lyonization occurs as an independent event in each of n founder cells and if it is assumed that such cells precede the pluripotent stem cell in ontogeny then the mean percent PMN positive for NBT in a heterozygote would be expected to be a binomial proportion with parameters p = 1/2 and n. The upper panels of Fig. 1 show the mean percentages of NBT-positive PMN expressed as a cumulative distribution (solid lines) and the cumulative binomial distributions corresponding to p = 1/2 and n = 4, 8, 16. The binomial distribution for n = 4 has steps that are too broad to fit the observed distribution well, whereas the binomial distribution for n = 16 lies systematically above the observed in the range where NJ3T-positive PMN exceed 50%. The binomial distribution for n = 8 has neither drawback; moreover, the maximum vertical distance between this pair of distributions is the smallest of the three cases (see legend to Fig. 1) .
The data collected on the 11 heterozygotes were also used to estimate the number of pluripotent stem cells actively supporting hematopoiesis. This estimate is based partly on the variation in the percent PMN positive for NBT within subjects which was found to be quite limited (standard deviations ranged from The number of pluripotent stem cells (m) was estimated by the method described by Burton et al. (7) from the relation m = 104p(1 -p)/S2, where p is the proportion of NBT-positive stem cells and s2, the variance due to intrinsic variability (the latter is expressed in percent; see "Statistical methods,," paragraph b). The proportion, p, was calculated to be 0.611 from data collected on an extensively studied heterozygote (a in Fig. 2 ) and the variance, s2, to be 5.13 from pooled data collected on the same heterozygote as well as three others. Thus, m, the number ofpluripotent stem cells was estimated to be 463. Additional estimates of m were obtained from calculated values ofp from the three remaining extensively studied heterozygotes and found to be 408, 407, and 467, respectively. Conservative estimates of m were also computed by assuming that all of the observed variability was due to clonal heterogeneity, i.e., that s2 = 21.92 and values 108, 95, 95, and 109, respectively, were obtained.
The above results were derived by determining the number of pluripotent stem cells needed to account for the variability observed among proportions of NBT-positive neutrophils in an individual heterozygote. The inverse relationship was also studied by determining the amount of variability in such proportions of NBT-positive neutrophils that would result from the sustained production of a given number of stem cell clones. For this, a steady-state model of bone marrow PMN production was simulated by computer (see "Statistical methods," paragraph c). To afford comparison of the output from the simulation with data obtained from patients the chance of selecting a NBT-positive clone (p) was taken to be 0.61 1, the average for the most extensively studied heterozygote (U in Fig. 2) . Three values of the number of stem cell clones (m) were chosen: 27, 108, and 432; these are centered (by ratio) around a conservative estimate of The results shown in Fig. 3 (9) . The observed variation in the mean percent normal PMN among the 11 heterozygotes studied is consistent with the distribution expected if inactivation of one ofthe X-chromosomes occurred at random when about eight founder cells for the hemotopoietic system are present. This estimate is in the same range (5-10 cell stage) as those found in two studies examining human X-linked glucose-6-phosphate dehydrogenase deficiency (10, I 1) but is lower than the figure (16 cell stage) noted in a third study (12) .
In contrast, only limited variation in the percent normal PMN was observed within extensive series of determinations made on blood from individual heterozygotes. This finding, in conjunction with the clonal succession theory (6) sources of variability other than that originating in the clonal selection process and hence may have seriously underestimated the required number of clones. On the other hand, the discrepancy between the two sets of results may be explained in part by the difference in size ofthe two hematopoietic systems studied.
The data reported in this paper consist of collected series of proportions of normal PMN observed in a group of CGD heterozygotes. These data are used to draw inferences about two well-known models ofcellular development, the Lyon hypothesis (4) and the clonal selection theory of hematopoiesis (6) . It is generally assumed that the neutrophil first makes its appearance many generations after the occurrence ofthe Lyon phenomenon and at least several generations after selection has occurred from the pool of nondividing pluripotent stem cells. The proportion of normal neutrophils thus serves as an indicator of events that have occurred in the recent and remote past. Accordingly, the inferences based on such data as we have collected are conditioned by a number of unavoidable assumptions, in particular, that data collected with neutrophils can be extended broadly to hematopoiesis; hence our inferences should be treated with some caution. Nevertheless, until more direct methods ofstudying the Lyon hypothesis and the clonal selection theory ofhematopoiesis are devised, such evidence is of interest, particularly because it relates to both models and hence draws attention to possible connections between these widely separated phenomena in cellular development.
